| NDC Code | 43742-2036-1 |
| Package Description | 30 mL in 1 BOTTLE, DROPPER (43742-2036-1) |
| Product NDC | 43742-2036 |
| Product Type Name | HUMAN OTC DRUG |
| Proprietary Name | Vir Combination |
| Non-Proprietary Name | Influenzinum (2020-2021), Herpes Simplex 1 Nosode, Herpes Simplex 2 Nosode, Human Herpesvirus 6a, Human Herpesvirus 6b, Cytomegalovirus Nosode, Hepatitis B Nosode, Adenoviren Nosode, Epstein-barr Virus Nosode |
| Dosage Form | LIQUID |
| Usage | ORAL |
| Start Marketing Date | 20210909 |
| End Marketing Date | 20261001 |
| Marketing Category Name | UNAPPROVED HOMEOPATHIC |
| Manufacturer | Deseret Biologicals, Inc. |
| Substance Name | HEPATITIS B VIRUS; HUMAN ADENOVIRUS B SEROTYPE 7 STRAIN 55142 ANTIGEN; HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 ANTIGEN; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 5; HUMAN HERPESVIRUS 6; INFLUENZA A VIRUS A/GUANGDONG-MAONAN/SWL1536/2019 CNIC-1909 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED); INFLUENZA A VIRUS A/HONG KONG/2671/2019 IVR-208 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED); INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN (FORMALDEHYDE INACTIVATED); INFLUENZA B VIRUS B/WASHINGTON/02/2019 ANTIGEN (FORMALDEHYDE INACTIVATED) |
| Strength | 33; 12; 12; 15; 15; 16; 18; 15; 12; 12; 12; 12 |
| Strength Unit | [hp_X]/mL; [hp_X]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL |
| Pharmacy Classes | Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Live Human Adenovirus Type 4 Vaccine [EPC], Live Human Adenovirus Type 7 Vaccine [EPC], Vaccines, Adenovirus [Chemical/Ingredient], Vaccines, Adenovirus [Chemical/Ingredient], Vaccines, Live, Unattenuated [Chemical/Ingredient], Vaccines, Live, Unattenuated [Chemical/Ingredient] |